Dendritic cell oncovaccines



Cite item

Full Text

Abstract

Continuously increasing cancer incidence in Russia leads to the development of new approaches to the treatment of malignant neoplasms. One such approach is to provide vaccines based on dendritic cells, which are capable of presenting tumor-associated antigens cytotoxic lymphocytes, thereby stimulating the immune system to eliminate the tumor. The results of the preclinical and clinical trials have shown that dendritic cells vaccination is a safe treatment. However, there is limited the therapeutic effect of these vaccines associated with formation in tumor focus powerful immunosuppressive microenvironment. The aim of this study is to compare the effectiveness of known methods of cultivation, maturation, antigen loading of dendritic cells, methods of introduction and to overcome the phenomenon of immunological tolerance in the organism for the tumor through the use of immune adjuvants; the means of monitoring the specific anti-tumor response in the organism.

About the authors

Stepan Andreyevich Peleshok

S. M. Kirov Military Medical Academy, Saint Petersburg

Author for correspondence.

Oleg Aleksandrovich Nagibovich

S. M. Kirov Military Medical Academy, Saint Petersburg

Oleg Vyacheslavovich Protasov

S. M. Kirov Military Medical Academy, Saint Petersburg

Igor Albertovich Ivanov

S. M. Kirov Military Medical Academy, Saint Petersburg

Ilya Sergeevich Usankin

S. M. Kirov Military Medical Academy, Saint Petersburg

References

  1. Балдуева И. А., Новик А. В., Моисеенко В. М. и др. Клиническое исследование вакцины на основе аутологичных дендритных клеток у больных с меланомой кожи. Вопросы онкологии. 2012; 58: 212-21.
  2. Горохов М. С., Корнеев М. Л. Основные виды противоопухолевых вакцин. Электронный журнал: эпидемиология, гигиена и санитария: профилактика. 2010; 1. http://www.rosmedportal.com/index.php?option=com_content&view=article&id=119 (23.08.2016).
  3. Нагибович О. А., Пелешок С. А., Болехан В. Н. и др. Противоопухолевые вакцины на основе дендритных клеток. Физика - наукам о жизни: тез. докл. Первой российской конференции. СПб.: ФТИ им. А. Ф. Иоффе; 2016. 115.
  4. Олюшин В. Е., Филатов М. В., Улитин А. Ю. и др. Специфическая противоопухолевая иммунотерапия на основе дендритных клеток в комплексном лечении больных злокачественными глиомами. СПб.: РНХИ; 2012. 212.
  5. Agostinis P., Berg K., Cengel K. A. et al. Photodynamic therapy of cancer: an update. CA: Cancer J. Clin. 2011; 61 (4): 250-81. doi: 10.3322/caac.20114.
  6. AnguilleS., LionE., vandenBerghJ. et al. Interleukin-15dendritic cells as vaccine candidates for cancer immunotherapy. Hum. Vaccin. Immunother. 2013; 9 (9): 1956-61. doi: 10.4161/hv.25373.
  7. Anguille S., Smits E. L., Lion E. et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014; 15 (7): e257-67. doi: 10.1016/S1470-2045(13)70585-0.
  8. Ardon H., van Gool S. W., Verschuere T. et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol. Immunother. 2012; 61 (11): 2033-44. doi: 10.1007/s00262-012-1261-1.
  9. Banchereau J., Briere F., Caux C. et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000; 18: 767-811. doi: 10.1146/annurev.immunol.18.1.767.
  10. Begovic M., Herberman R. B., Gorelik E. Ultraviolet light-induced increase in tumor cell susceptibility to TNF-dependent and TNF-independent natural cell-mediated cytotoxicity. Cell. Immunol. 1991; 138 (2): 349-59. doi: 10.1016/0008-8749(91)90159-9.
  11. Brackett C. M., Kojouharov B., Veith J. et al. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Рroc. Natl. Acad. Sci. USA. 2016; 113 (7): 874-83. doi: 10.1073/pnas.1521359113.
  12. Brahmer J., Reckamp K. L., Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015; 373 (2): 123-35. DOI: 10.1056/ NEJMoa1504627.
  13. Brusa D., Garetto S., Chiorino G. et al. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine. 2008; 26 (50): 6422-32. doi: 10.1016/j.vaccine.2008.08.063.
  14. Canter R. J., Grossenbacher S. K., Ames E. et al. Immunetargeting of cancer stem cells in gastrointestinal oncology. J. Gastrointest. Oncol. 2016; 7 (1): 1-10. DOI: 10.3978/j. issn.2078-6891.2015.066.
  15. Cao J. X., Zhang X. Y., Liu J. L. et al. Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis. PLoS One. 2014; 9 (9): e107173. doi: 10.1371/journal.pone.0107173.
  16. Carreno B. M., Becker-Hapak M., Huang A. et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J. Clin. Invest. 2013; 123 (8): 3383-94. doi: 10.1172/JCI68395.
  17. Chen H. M., Wang P. H., Chen S. S. et al. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunol. Immunother. 2012; 61 (11): 1989-2002. doi: 10.1007/s00262-012-1258-9.
  18. Chiang C. L., Kandalaft L. E., Tanyi J. et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin. Cancer. Res. 2013; 19 (17): 4801-15. doi: 10.1158/1078-0432.CCR-13-1185.
  19. Diaconu I., Cerullo V., Hirvinen M. L. et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 2012; 72 (9): 2327-38. doi: 10.1158/0008-5472.CAN-11-2975.
  20. Dong T., Yi T., Yang M. et al. Co-operation of α-galactosy-lceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model. Biochem. J. 2016; 473 (1): 7-19. doi: 10.1042/BJ20150129.
  21. Donnelly O. G., Errington-Mais F., Steele L. et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2013; 20 (1): 7-15. doi: 10.1038/gt.2011.205.
  22. Duarte S., Momier D., Baque P. et al. Preventive cancer stem cell-based vaccination reduces liver metastasis development in a rat colon carcinoma syngeneic model. Stem Cells. 2013; 31 (3): 423-32. doi: 10.1002/stem.1292.
  23. Elens I., de Vleeschouwer S., Pauwels F. et al. Resection and immunotherapy for recurrent grade III glioma. Neuro Oncol. 2012; 14: 61. doi: 10.5402/2012/530179.
  24. Etminan N., Eters C., Lakbir D. et al. Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro. Br. J. Cancer. 2011; 105 (7): 961-9. doi: 10.1038/bjc.2011.327.
  25. Fadul C. E., Fisher J. L., Hampton T. H. et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccine ation after radiation chemo therapy. J. Immunother. 2011; 34 (4): 382-9. doi: 10.1097/CJI.0b013e318215e300.
  26. Fan-Qin W., Wei S., Thian-Sze W. et al. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. J. Exp. Clin. Cancer. Res. 2016; 35: 18. doi: 10.1186/s13046-016-0295-1.
  27. Feng H., Zeng Y., Graner M. W. et al. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T-cells. Blood. 2002; 100 (12): 4108-15. DOI: 10.1182/ blood-2002-05-1389.
  28. Fucikova J., Moserova I., Truxova I. et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int. J. Cancer. 2014; 135 (5): 1165-77. doi: 10.1002/ijc.28766.
  29. Garg A. D., Agostinis P. ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses. Photochem. Photobiol. Sci. 2014; 13 (3): 474-87. DOI: 1010.1039/c3pp50333j.
  30. Garg A. D., Bose M., Ahmed M. I. et al. In vitro studies on erythrosine-based photodynamic therapy of malignant and pre-malignant oral epithelial cells. PLoS One. 2012; 7 (4): e34475. doi: 10.1371/journal.pone.0034475.
  31. Garg A. D., Dudek A. M., Agostinis P. Autophagy-dependent suppression of cancer immunogenicity and effector mechanisms of innate and adaptive immunity. Oncoimmunology. 2013; 2 (10): e26260. doi: 10.4161/onci.26260.
  32. Garg A. D., Galluzzi L., Apetoh L. et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front. Immunol. 2015; 6: 588. doi: 10.3389/fimmu. 2015.00588.
  33. Garg A. D., Krysko D. V., Verfaillie T. et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012; 31 (5): 1062-79. doi: 10.1038/emboj.2011.497.
  34. Garg A. D., Nowis D., Golab J. et al. Photodynamic therapy: illuminating the road from cell death towards antitumour immunity. Apoptosis. 2010; 15 (9): 1050-71. doi: 10.1007/s10495-010-0479-7.
  35. Hodi F. S., O’Day S. J., McDermott D. F. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010; 363 (8): 711-23. doi: 10.1056/NEJMoa 1003466.
  36. Jie X., Hua L., Jiang W. etal. Clinical application of adendritic cell vaccine raised against heat-shocked glioblastoma. Cell. Biochem. Biophys. 2012; 62 (1): 91-9. doi: 10.1007/s12013-011-9265-6.
  37. Jung N. C., Kim H. J., Kang M. S. et al. Photodynamic therapy-mediated DC immunotherapy is highly effective for the inhibition of established solid tumors. Cancer Lett. 2012; 324 (1): 58-65. doi: 10.1016/j.canlet.2012.04.024.
  38. Kepp O., Senovilla L., Vitale I. et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014; 3 (9): e955691. doi: 10.4161/21624011. 2014.955691.
  39. Kirkwood J. M., Butterfield L. H., Tarhini A. A. et al. Immuno- therapy of cancer in 2012. CA: Cancer. J. Clin. 2012; 62 (5): 309-35. doi: 10.3322/caac.20132.
  40. Koido S., Ohkusa T., Homma S. et al. Immunotherapy for colorectal cancer. World. J. Gastroenterol. 2013; 19: 8531-8542. doi: 10.3748/wjg.v19.i46.8531.
  41. Koks C. A., de Vleeschouwer S., Graf N. et al. Immune suppression during oncolytic virotherapy for high-grade glioma. Yes or No? J. Cancer. 2015; 6 (3): 203-17. doi: 10.7150/jca.10640.
  42. Koks C. A., Garg A. D., Ehrhardt M. et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int. J. Cancer. 2015; 136 (5): e313-25. doi: 10.1002/ijc.29202.
  43. Kreutz M., Tacken P. J., Figdor C. G. Targeting dendritic cells - why bother? Blood. 2013; 121: 2836-44. doi: 10.1182/blood-2012-09-452078.
  44. Krishnadas D. K., Shapiro T., Lucas K. Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma. Pediatrics. 2013; 131: e336-41. doi: 10.1542/peds. 2012-0376.
  45. Kroemer G., Galluzzi L., Kepp O. et al. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 2013; 31: 51-72. doi: 10.1146/annurev-immunol-032712-100008.
  46. Krysko D. V., Garg A. D., Kaczmarek A. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer. 2012; 12 (12): 860-75. doi: 10.1038/nrc3380.
  47. Lesterhuis W. J., de Vries I. J., Schreibelt G. et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin. Cancer Res. 2011; 17 (17): 5725-35. doi: 10.1158/1078-0432.CCR-11-1261.
  48. Levenga H., Schaap N., Maas F. et al. Partial T cell-depleted allogeneic stem cell transplantation following reducedintensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma. Biol. Blood. Marrow. Transplant. 2010; 16: 320-32. DOI: 10.1016/j. bbmt.2009.10.006.
  49. Lindemans C. A., Chiesa R., Amrolia P. J. et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood. 2014; 123: 126-32. DOI: 10.1182/ blood-2013-05-502385.
  50. Mar V. J., Wong S. Q., Li J. et al. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin. Cancer. Res. 2013; 19 (17): 4589-98. doi: 10.1158/1078-0432.CCR-13-0398.
  51. Miller Y. I., Choi S. H., Wiesner P. et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 2011; 108 (2): 235-48. doi: 10.1161/CIRCRESAHA.110.223875.
  52. Mine T., Matsueda S., Li Y. et al. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer. Immunol. Immunother. 2009; 58: 1185-94. doi: 10.1007/s00262-008-0623-1.
  53. Mitra S., Benjamin R., Giesselman B. R. et al. Tumor response to mTHPC-mediated photodynamic therapy exhibits strong correlation with extracellular release of HSP70. Lasers. Surg. Med. 2011; 43 (7): 632-43. doi: 10.1002/lsm.21108.
  54. Miyamoto S., Inoue H., Nakamura T. et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer. Res. 2012; 72 (10): 2609-21. doi: 10.1158/0008-5472.CAN-11-3185.
  55. Moghaddam A. E., Gartlan K. H., Kong L. et al. Reactive carbonyls are a major Th2-inducing damage-associated molecular pattern generated by oxidative stress. J. Immunol. 2011; 187 (4): 1626-33. doi: 10.4049/jimmunol.1003906.
  56. Nakai N., Hartmann G., Kishimoto S. et al. Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell & Melanoma Research. 2010; 23 (5): 607-19. doi: 10.1111/j.1755-148X. 2010.00736.x.
  57. Nierkens S., Janssen E. M. Harnessing dendritic cells for tumor antigen presentation. Cancers. 2011; 3: 2195-213. doi: 10.3390/cancers3022195.
  58. Okada H., Kalinski P., Ueda R. et al. Induction of CD8 T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}- type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 2011; 29 (3): 330-6. doi: 10.1200/JCO.2010.30.7744.
  59. Panzarini E., Inguscio V., Fimia G. M. et al. Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of damage-associated molecular patterns (DAMPs) in human HeLa cells. PLoS One. 2014; 9 (8): e105778. doi: 10.1371/journal.pone.0105778.
  60. Plantinga M., de Haar C., Nierkens S. et al. Dendritic cell therapy in allogeneic hematopoietic stem cell transplantation: an effective strategy toward better disease control? Front. Immunol. 2014; 5: 218. doi: 10.3389/fimmu. 2014.00218.
  61. Prins R. M., Wang X., Soto H. et al. Comparison of glioma- associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J. Immunother. 2013; 36 (2): 152-7. DOI: 10.1097/ CJI.0b013e3182811ae4.
  62. Provasi E., Genovese P., Lombardo A. et al. Editing T-cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 2012; 18 (5): 807-15. doi: 10.1038/nm.2700.
  63. Radford K. J., Tullett K. M., Lahoud M. H. Science direct dendritic cells and cancer immunotherapy. Curr. Opin. Immunol. 2014; 27: 26-32. doi: 10.1016/j.coi.2014.01.005.
  64. Ricupito A., Grioni M., Calcinotto A. et al. Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer. Res. 2013; 73: 3545-54. doi: 10.1158/0008-5472.CAN-12-2449.
  65. Robert C., Ribas A., Wolchok J. D. et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384 (9948): 1109-17. doi: 10.1016/S0140-6736(14)60958-2.
  66. Romano E., Rossi M., Ratzinger G. et al. Peptide-loaded langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin. Cancer. Res. 2011; 17 (7): 1984-97. doi: 10.1158/1078-0432.CCR-10-3421.
  67. Sabado R. L., Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy. 2010; 2 (1): 37-56. doi: 10.2217/imt.09.43.
  68. Schirrmacher V., Stücker W., Lulei M. et al. Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report. Immunotherapy. 2015; 7 (8): 855-60. doi: 10.2217/imt.15.48.
  69. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J. Natl. Cancer. Inst. 2012; 104 (8): 599-613. doi: 10.1093/jnci/djs033.
  70. Schultz R. K. R., Baker K. S., Boelens J. J. et al. Challenges and opportunities for international cooperative studies in pediatric hematopoietic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol. Blood. Marrow. Transplant. 2013; 19: 1279-87. doi: 10.1016/j.bbmt. 2013.07.006.
  71. Selzer E., Hebar A. Basic principles of molecular effects of irradiation. Wien. Med. Wochenschr. 2012; 162 (3-4): 47- 54. doi: 10.1007/s10354-012-0052-9.
  72. Shaw P. J., Kan F., Woo A. K. et al. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood. 2010; 116: 4007-15. doi: 10.1182/blood-2010-01-261958.
  73. Shi H., Cao T., Connolly J. E. et al. Hyperthermia enhances CTL cross-priming. J. Immunol. 2006; 176 (4): 2134-41. doi: 10.4049/jimmunol.176.4.2134.
  74. Shimodaira S. Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms’ Tumor 1 in Patients with Advanced Colorectal Cancer. Vaccines. 2015; 3 (4): 1004-18. doi: 10.3390/vaccines3041004.
  75. Shimodaira S., Hirabayashi K., Koya T. et al. An update on Dendritic Cell-Based Cancer Immunotherapy. Immunome. Res. 2016; 12: 106. doi: 10.4172/1745-7580.10000106.
  76. Stangl S., Themelis G., Friedrich L. et al. Detection of irradiation-induced, membrane heat shock protein 70 (HSP70) in mouse tumors using HSP70 Fab fragment. Radiother. Oncol. 2011; 99 (3): 313-6. doi: 10.1016/j.radonc.2011.05.051.
  77. Suzuki Y., Mimura K., Yoshimoto Y. et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 2012; 72 (16): 3967-76. doi: 10.1158/0008-5472.CAN-12-0851.
  78. Ueno H., Schmitt N., Klechevsky E. et al. Harnessing human dendritic cell subsets for medicine. Immunol. Rev. 2010; 234 (1): 199-212. doi: 10.1111/j.0105-2896.2009.00884.x.
  79. Vandenberk L., Belmans J., van Woensel M. et al. Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. Front. Immunol. 2016; 6: 663. doi: 10.3389/fimmu.2015.00663.
  80. Vandenberk L., Garg A. D., Verschuere T. et al. Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma. Oncoimmunology. 2015. doi: 10.1080/2162402X.2015.1083669.
  81. Van Tendeloo V. F., van de Velde A., van Driessche A. et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl. Acad. Sci. USA. 2010; 107: 13824-9. doi: 10.1073/pnas.1008051107.
  82. Verfaillie T., Rubio N., Garg A. D. et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell. Death. Differ. 2012; 19 (11): 1880-91. doi: 10.1038/cdd.2012.74.
  83. Weiss E. M., Meister S., Janko C. et al. High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features. J. Immunotoxicol. 2010; 7 (3): 194-204. doi: 10.3109/15476911003657414.
  84. Woller N., Knocke S., Mundt B. et al. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J. Clin. Invest. 2011; 121 (7): 2570-82. doi: 10.1172/JCI45585.
  85. Yang H., Zhou P., Huang H. et al. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int. J. Cancer. 2009; 124 (10): 2450-9. doi: 10.1002/ijc.24195.
  86. Yi Y., Han J., Zhao L. et al. Immune responses of dendritic cells combined with tumor-derived autophagosome vaccine on hepatocellular carcinoma. Chin. J. Cancer. Res. 2015; 27 (6): 597-603. doi: 10.3978/j.issn.1000-9604.2015.12.07.
  87. Yin T., Shi P., Gou S. et al. Dendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitro. PLoS One. 2014; 9 (12): e114581. doi: 10.1371/journal.pone.0114581.
  88. Zappasodi R., Pupa S. M., Ghedini G. C. et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer. Res. 2010; 70 (22): 9062-72. DOI: 10.1158/ 0008-5472.CAN-10-1825.
  89. Zhang S. N., Zhang S. N., Choi I. K. et al. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol. Ther. 2011; 19 (8): 1558-68. doi: 10.1038/mt.2011.29.
  90. Zhao M., Li H., Li L. et al. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp. Ther. Med. 2014; 7 (5): 1403-1407. doi: 10.3892/etm.2014.1574.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 77760 от 10.02.2020.